Frontlight ResearchEarly access
Taking peopleNo phase
BosSTENT ImpLant to trEat debilitatiNg Pulse-synchronous Tinnitus
Key facts
- Who runs it
- Sonorous NV, Inc
- Where
- Canada and France6 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 90 people, planned
- Started
- 1 Feb 2026
- Expected to end
- Jul 2028
- Type of study
- Interventional
- Treatments tested
- BosSTENT implantation
- Record updated
- 28 August 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- Male or female ≥18 - 80 years old
- Able to provide informed consent to participate in the study
- Severe or catastrophic PST (THI grade ≥ 4; THI score ≥ 58) that responds to jugular vein compression
- Cerebral venous sinus stenosis with the following characteristics:; Transverse cerebral venous sinus; >50% stenosis by computed tomography venogram (CTV), magnetic resonance venogram (MRV), or catheter cerebral angiography; Vessel diameter amenable to sizing according to Table 1 below without the need to undersize
- Attempted PST amelioration with at least one non-invasive therapy (i.e., refractory to non-invasive therapy)
- Willing to comply with protocol requirements and return to the treatment center for all required clinical evaluations and follow-up
- Life expectancy >12 months
Who cannot take part
- Previously implanted stent in the target vessel
- Contraindication to anticoagulant and/or antiplatelet therapy or thrombolytic drugs
- Hypercoagulable state or hemorrhagic or coagulation deficiency refractory to medical therapy
- Pregnant or nursing women (females of childbearing potential who are less than 45 years old must have a pregnancy test and provide written proof that they are not pregnant prior to inclusion)
- Dural cerebral venous sinus stenosis secondary to an underlying condition (e.g. brain tumor) that may be treated by alternative established therapies (e.g., surgery, embolization)
- History of severe allergy to contrast/contrast media or nickel
- Dural arteriovenous fistula or arteriovenous malformation
- History of untreated atrial fibrillation, untreated/uncontrollable hypertension, or other stroke factors
- History of deep vein thrombosis or pulmonary embolism
- History of heart failure, dilated cardiomyopathy, or congenital heart conditions
- Evidence of an active systemic infection
- Venous sinus thrombosis, jugular compression, venous aberrant or tortuous anatomy that would prevent the safe delivery and deployment of the BosSTENT to the target treatment zone
- Otologic disorders that may confound PST assessments, including, but not limited to misophonia or hyperacusis
- Suffered a stroke within the past 6 months
- Other clinical conditions, that in the opinion of the Investigator significantly compromise the ability to perform a safe and/or effective procedure
- Platelet count <100x109/L (100,000/µL)
- Target vessel size that does not fall within the indicated range per Table 1 of the IFU
- Non-pulse-synchronous tinnitus
- Current diagnosis of papilledema
- Arterial stenosis, dissection, or aneurysm
- PST due to causes not related to cerebral venous sinus stenosis
- Cerebral venous sinus diverticulum that, in the Investigator's opinion, requires treatment other than stenting (e.g., coiling)
- Participation in another investigational protocol
- Immuno-compromised
- Incapacitated, mentally compromised or otherwise incapable of understanding and/or providing informed consent
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is evaluating the safety and clinical performance of the BosSTENT, a new stent designed specifically for treating pulse-synchronous tinnitus due to venous sinus stenosis. The study will evaluate the long-term safety of the BosSTENT as well as its impact on the severity of pulse-synchronous tinnitus.
The group in the trial
- BosSTENTTreatment being tested
Treatment: BosSTENT implantation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Fit questions
- Built from NCT07070089, who can take part
- Record updated
- 28 August 2026